Site Maintenance will take place from 4:00 PM on 2024-04-29 to 9:00 AM on 2024-05-01.
Please do not make any content change during this time, otherwise all the changes will be lost.

Researcher

Miss Noemi Auxiliadora Fuentes Bolanos

Biography

Noemi Fuentes, M.D., PhD, is a clinical academic originally from Spain. She is a post-doctoral researcher in Germline Cancer Risk at the Children's Cancer Institute and dual-trained in Paediatric Oncology and Clinical Genetics (Cancer) by RACP. She completed international training in Spain, the United Kingdom (The Royal Marsden Hospital) and Australia (Sydney Children’s Hospital) and is certified as a clinician by the General Medical College...view more

Noemi Fuentes, M.D., PhD, is a clinical academic originally from Spain. She is a post-doctoral researcher in Germline Cancer Risk at the Children's Cancer Institute and dual-trained in Paediatric Oncology and Clinical Genetics (Cancer) by RACP. She completed international training in Spain, the United Kingdom (The Royal Marsden Hospital) and Australia (Sydney Children’s Hospital) and is certified as a clinician by the General Medical College in the UK and AHPRA in Australia. 

After receiving her medical degree, she completed a Master of Sciences in Biomedicine before undertaking a PhD in Epidemiology in 2017. Currnetly, she is a Senior Lecturer at the School of Medical Sciences (University of New South Wales). 

Noemi’s primary research interest is Germline Cancer Risk in children, adolescents, and young adults and its implications for diagnosis and management of childhood cancer. She joined the national ZERO Childhood Cancer Program (Australia) in 2019.  

Her current role focuses on integrative analysis and interpretation of somatic and germline findings in childhood cancer and translating these findings into meaningful clinical recommendations. Noemi is involved in developing several national clinical guidelines for the surveillance of children with cancer predisposition syndromes. Most recently, Noemi has been fundamental in developing the Cancer PREDisposItion in Childhood by Trio-based sequencing (PREDICT) Study, a state-wide pilot study that analyses family-based whole genome sequencing in every newly diagnosed child and AYA with cancer. 

View less